Endothelins: Vasoactive Peptids
Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstricto...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Hasan Erdoğan [verfasserIn] Ersin Fadıllıoğlu [verfasserIn] M. Hanifi Emre [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Türkisch |
| Erschienen: |
2013 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Namık Kemal Tıp Dergisi - Galenos Yayincilik, 2022, 1(2013), 2, Seite 137-145 |
|---|---|
| Übergeordnetes Werk: |
volume:1 ; year:2013 ; number:2 ; pages:137-145 |
| Links: |
|---|
| Katalog-ID: |
DOAJ015659305 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ015659305 | ||
| 003 | DE-627 | ||
| 005 | 20230501192544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2013 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ015659305 | ||
| 035 | |a (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a tur | ||
| 100 | 0 | |a Hasan Erdoğan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelins: Vasoactive Peptids |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. | ||
| 650 | 4 | |a endothelins | |
| 650 | 4 | |a endothelin-1 | |
| 650 | 4 | |a endothelin receptor antagonists | |
| 650 | 4 | |a autacoids | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Ersin Fadıllıoğlu |e verfasserin |4 aut | |
| 700 | 0 | |a M. Hanifi Emre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Namık Kemal Tıp Dergisi |d Galenos Yayincilik, 2022 |g 1(2013), 2, Seite 137-145 |w (DE-627)1830311751 |x 25870262 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2013 |g number:2 |g pages:137-145 |
| 856 | 4 | 0 | |u https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 |z kostenfrei |
| 856 | 4 | 0 | |u http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2587-0262 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2013 |e 2 |h 137-145 | ||
| author_variant |
h e he e f ef m h e mhe |
|---|---|
| matchkey_str |
article:25870262:2013----::nohlnvsatv |
| hierarchy_sort_str |
2013 |
| publishDate |
2013 |
| allfields |
(DE-627)DOAJ015659305 (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 DE-627 ger DE-627 rakwb eng tur Hasan Erdoğan verfasserin aut Endothelins: Vasoactive Peptids 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. endothelins endothelin-1 endothelin receptor antagonists autacoids Medicine R Ersin Fadıllıoğlu verfasserin aut M. Hanifi Emre verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 1(2013), 2, Seite 137-145 (DE-627)1830311751 25870262 nnns volume:1 year:2013 number:2 pages:137-145 https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 1 2013 2 137-145 |
| spelling |
(DE-627)DOAJ015659305 (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 DE-627 ger DE-627 rakwb eng tur Hasan Erdoğan verfasserin aut Endothelins: Vasoactive Peptids 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. endothelins endothelin-1 endothelin receptor antagonists autacoids Medicine R Ersin Fadıllıoğlu verfasserin aut M. Hanifi Emre verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 1(2013), 2, Seite 137-145 (DE-627)1830311751 25870262 nnns volume:1 year:2013 number:2 pages:137-145 https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 1 2013 2 137-145 |
| allfields_unstemmed |
(DE-627)DOAJ015659305 (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 DE-627 ger DE-627 rakwb eng tur Hasan Erdoğan verfasserin aut Endothelins: Vasoactive Peptids 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. endothelins endothelin-1 endothelin receptor antagonists autacoids Medicine R Ersin Fadıllıoğlu verfasserin aut M. Hanifi Emre verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 1(2013), 2, Seite 137-145 (DE-627)1830311751 25870262 nnns volume:1 year:2013 number:2 pages:137-145 https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 1 2013 2 137-145 |
| allfieldsGer |
(DE-627)DOAJ015659305 (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 DE-627 ger DE-627 rakwb eng tur Hasan Erdoğan verfasserin aut Endothelins: Vasoactive Peptids 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. endothelins endothelin-1 endothelin receptor antagonists autacoids Medicine R Ersin Fadıllıoğlu verfasserin aut M. Hanifi Emre verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 1(2013), 2, Seite 137-145 (DE-627)1830311751 25870262 nnns volume:1 year:2013 number:2 pages:137-145 https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 1 2013 2 137-145 |
| allfieldsSound |
(DE-627)DOAJ015659305 (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 DE-627 ger DE-627 rakwb eng tur Hasan Erdoğan verfasserin aut Endothelins: Vasoactive Peptids 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. endothelins endothelin-1 endothelin receptor antagonists autacoids Medicine R Ersin Fadıllıoğlu verfasserin aut M. Hanifi Emre verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 1(2013), 2, Seite 137-145 (DE-627)1830311751 25870262 nnns volume:1 year:2013 number:2 pages:137-145 https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 1 2013 2 137-145 |
| language |
English Turkish |
| source |
In Namık Kemal Tıp Dergisi 1(2013), 2, Seite 137-145 volume:1 year:2013 number:2 pages:137-145 |
| sourceStr |
In Namık Kemal Tıp Dergisi 1(2013), 2, Seite 137-145 volume:1 year:2013 number:2 pages:137-145 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
endothelins endothelin-1 endothelin receptor antagonists autacoids Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Namık Kemal Tıp Dergisi |
| authorswithroles_txt_mv |
Hasan Erdoğan @@aut@@ Ersin Fadıllıoğlu @@aut@@ M. Hanifi Emre @@aut@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
1830311751 |
| id |
DOAJ015659305 |
| language_de |
englisch türkisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ015659305</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501192544.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ015659305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf105213dbf214163ac476c4f5dae6039</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">tur</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hasan Erdoğan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Endothelins: Vasoactive Peptids</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endothelins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endothelin-1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endothelin receptor antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autacoids</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ersin Fadıllıoğlu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Hanifi Emre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Namık Kemal Tıp Dergisi</subfield><subfield code="d">Galenos Yayincilik, 2022</subfield><subfield code="g">1(2013), 2, Seite 137-145</subfield><subfield code="w">(DE-627)1830311751</subfield><subfield code="x">25870262</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:137-145</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f105213dbf214163ac476c4f5dae6039</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-0262</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="h">137-145</subfield></datafield></record></collection>
|
| author |
Hasan Erdoğan |
| spellingShingle |
Hasan Erdoğan misc endothelins misc endothelin-1 misc endothelin receptor antagonists misc autacoids misc Medicine misc R Endothelins: Vasoactive Peptids |
| authorStr |
Hasan Erdoğan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1830311751 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
25870262 |
| topic_title |
Endothelins: Vasoactive Peptids endothelins endothelin-1 endothelin receptor antagonists autacoids |
| topic |
misc endothelins misc endothelin-1 misc endothelin receptor antagonists misc autacoids misc Medicine misc R |
| topic_unstemmed |
misc endothelins misc endothelin-1 misc endothelin receptor antagonists misc autacoids misc Medicine misc R |
| topic_browse |
misc endothelins misc endothelin-1 misc endothelin receptor antagonists misc autacoids misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Namık Kemal Tıp Dergisi |
| hierarchy_parent_id |
1830311751 |
| hierarchy_top_title |
Namık Kemal Tıp Dergisi |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1830311751 |
| title |
Endothelins: Vasoactive Peptids |
| ctrlnum |
(DE-627)DOAJ015659305 (DE-599)DOAJf105213dbf214163ac476c4f5dae6039 |
| title_full |
Endothelins: Vasoactive Peptids |
| author_sort |
Hasan Erdoğan |
| journal |
Namık Kemal Tıp Dergisi |
| journalStr |
Namık Kemal Tıp Dergisi |
| lang_code |
eng tur |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
txt |
| container_start_page |
137 |
| author_browse |
Hasan Erdoğan Ersin Fadıllıoğlu M. Hanifi Emre |
| container_volume |
1 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Hasan Erdoğan |
| author2-role |
verfasserin |
| title_sort |
endothelins: vasoactive peptids |
| title_auth |
Endothelins: Vasoactive Peptids |
| abstract |
Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. |
| abstractGer |
Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. |
| abstract_unstemmed |
Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Endothelins: Vasoactive Peptids |
| url |
https://doaj.org/article/f105213dbf214163ac476c4f5dae6039 http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585 https://doaj.org/toc/2587-0262 |
| remote_bool |
true |
| author2 |
Ersin Fadıllıoğlu M. Hanifi Emre |
| author2Str |
Ersin Fadıllıoğlu M. Hanifi Emre |
| ppnlink |
1830311751 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| up_date |
2024-07-03T16:16:14.501Z |
| _version_ |
1803575229941809152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ015659305</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501192544.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ015659305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf105213dbf214163ac476c4f5dae6039</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">tur</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hasan Erdoğan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Endothelins: Vasoactive Peptids</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endothelins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endothelin-1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endothelin receptor antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autacoids</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ersin Fadıllıoğlu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Hanifi Emre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Namık Kemal Tıp Dergisi</subfield><subfield code="d">Galenos Yayincilik, 2022</subfield><subfield code="g">1(2013), 2, Seite 137-145</subfield><subfield code="w">(DE-627)1830311751</subfield><subfield code="x">25870262</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:137-145</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f105213dbf214163ac476c4f5dae6039</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://namikkemalmedj.com/archives/archive-detail/article-preview/endothelins-vasoactive-peptids/41585</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-0262</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="h">137-145</subfield></datafield></record></collection>
|
| score |
7.400324 |